News Search Results
Feb 18, 2026, 02:36 ET BioArctic Interim Report for the period October - December 2025
strengthening our pipeline to take the next step as a company. Since then, we have strengthened our project portfolio with two new projects, one in Huntington's disease and one related to Parkinson´s disease, as well as advanced our existing projects.In the fourth quarter, we also nominated candidate
More news about: BioArctic
Feb 17, 2026, 13:57 ET QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit
misrepresented and/or failed to disclose that: (1) the design of uniQure's Pivotal Study (a study of uniQure's leading drug candidate in patients with Huntington's Disease) — including comparison of the Pivotal Study results to the ENROLL-HD external historical data set— was not fully approved by the U.S. Food
More news about: THE ROSEN LAW FIRM, P. A.
Feb 17, 2026, 08:44 ET Hahn & Hahn LLP to Sponsor The Huntington's Upcoming Exhibition "This Land Is …"
exhibition invites reflection on the foundational role of land in shaping American history, identity, and creative expression. Drawing on The Huntington's extraordinary library, art, and botanical collections, "This Land Is"… will explore the ideals of life, liberty, and the pursuit of happiness
More news about: Hahn & Hahn LLP
Feb 16, 2026, 14:33 ET Keep Memory Alive Honors Kenny Loggins and Hosts Star-Studded Lineup at 30th Anniversary of Power of Love Gala
diagnosis and treatment for individuals and families living with Alzheimer's disease, Lewy body, frontotemporal and other dementias; Parkinson's and Huntington's disease, multiple system atrophy and other movement disorders; and multiple sclerosis. With locations in Cleveland, Ohio; Weston, Fla., and headquarters
More news about: Keep Memory Alive
Feb 13, 2026, 08:00 ET Huntington Bank Wins 15 'Best Bank' Awards for Its Service to Small and Mid-Sized Businesses
Corts, Huntington's director of Regional Banking. "Our Regional Banking model helps us build strong, lasting partnerships. It helps us to support small businesses through every stage of their journey with the advice and solutions they need to keep moving forward successfully." Huntington's Middle
More news about: Huntington National Bank
Feb 13, 2026, 01:22 ET QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit
misrepresented and/or failed to disclose that: (1) the design of uniQure's Pivotal Study (a study of uniQure's leading drug candidate in patients with Huntington's Disease) — including comparison of the Pivotal Study results to the ENROLL-HD external historical data set— was not fully approved by the U.S. Food
More news about: THE ROSEN LAW FIRM, P. A.
Feb 12, 2026, 14:15 ET Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against uniQure N.V. (QURE) - Contact Kessler Topaz Meltzer & Check, LLP
ACTION LAWSUIT COMPLAINT ALLEGEGATIONS uniQure is a biotechnology company developing gene therapies for rare diseases, including Huntington's disease ("HD"). uniQure is incorporated in The Netherlands with its principal executive offices in Amsterdam, The Netherlands.The Company's
More news about: Kessler Topaz Meltzer & Check, LLP
Feb 11, 2026, 16:01 ET Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026
1,265INGREZZA sales guidance reflects expected net product sales of INGREZZA in tardive dyskinesia and chorea associated with Huntington's disease.R&D guidance reflects the continued advancement of the Company's pre-clinical and clinical portfolio including the Phase 3
More news about: Neurocrine Biosciences, Inc.
Feb 10, 2026, 12:21 ET Canary Speech and Intermountain Ventures Launch Groundbreaking Study to Identify Multiple Sclerosis Using Vocal Biomarkers
alternative to current methods. The company's passive listening technology, previously successful in identifying neurodegenerative diseases like Huntington's, Alzheimer's, and Parkinson's, will now be applied in this groundbreaking study.About Canary SpeechCanary Speech is a Utah-based,
More news about: Canary Speech
Feb 10, 2026, 12:17 ET PGA TOUR University Announces Huntington Bank as Official Sponsor
mission to identify the top players in collegiate golf and provide membership opportunities on PGA TOUR-affiliated tours. The partnership aligns with Huntington's focus on investing in people and long-term potential."Our partnership with PGA TOUR University reflects our belief in investing in potential
More news about: Huntington National Bank
Feb 10, 2026, 11:12 ET PGA TOUR University Announces Huntington Bank as Official Sponsor
mission to identify the top players in collegiate golf and provide membership opportunities on PGA TOUR-affiliated tours. The partnership aligns with Huntington's focus on investing in people and long-term potential."Our partnership with PGA TOUR University reflects our belief in investing in potential
More news about: The Huntington National Bank
Feb 05, 2026, 08:00 ET Huntington Bank Names Senthil Kumar Chief Risk Officer
Senthil will join Huntington's executive leadership team and report to Chief Executive Officer Steve Steinour. "I am thrilled to welcome Senthil to the executive team and into this critical role," Steinour said. "His proven leadership and wealth of experience will further Huntington's strong risk management
More news about: Huntington National Bank
Feb 03, 2026, 16:05 ET Huntington Bancshares Incorporated to Present at the 2026 UBS Financial Services Conference
Webcast InformationInterested investors may access the live audio webcast in the investor relations section of Huntington's website (www.huntington-ir.com). A replay of the webcast will be archived on the website.About
More news about: Huntington Bancshares Incorporated
Feb 02, 2026, 13:05 ET New research reveals how the brain turns experience into memory -- with help from a tiny protein
chaperone biology that we've long been missing," Si said.Amyloids are typically associated with neurodegenerative diseases such as Alzheimer's, Huntington's and Parkinsons. They form tightly packed, highly stable "detrimental" protein fibers that destroy brain cells, erasing the memories of their host.The
More news about: Stowers Institute for Medical Research
Feb 02, 2026, 07:30 ET Huntington Bank Completes Merger with Cadence Bank, Expanding Presence Across Texas and the South
This strategic partnership accelerates Huntington's growth initiatives across Texas and the South and brings immediate scale in Texas and Mississippi, where Huntington is now the eighth-largest bank
More news about: Huntington Bancshares Incorporated
Feb 01, 2026, 13:56 ET QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
2025, uniQure issued a press release revealing that the FDA notified the company that data for its AMT-130, an investigational gene therapy for Huntington's disease, did not provide sufficient evidence to support uniQure's Biologics License Application ("BLA") submission. Specifically, uniQure disclosed
More news about: Kessler Topaz Meltzer & Check, LLP
Jan 28, 2026, 17:31 ET DUB Inhibitors Market to Witness Strong Expansion Across 7MM by 2040 Driven by the Launch of Novel Therapeutics | DelveInsight
roles in neuronal protein homeostasis, making them attractive targets for neurodegenerative diseases, including Alzheimer's, Parkinson's, and Huntington's disease.Clinical development of DUB inhibitors is accelerating as the ubiquitin–proteasome system gains recognition as a central regulator
More news about: DelveInsight Business Research, LLP
Jan 28, 2026, 12:57 ET Skyhawk Therapeutics gibt Neun-Monats-Zwischenergebnisse bei Patienten aus der klinischen Phase-1-Studie mit SKY-0515 zur Behandlung der Huntington-Krankheit bekannt
Die Ergebnisse nach neun Monaten zeigen eine durchschnittliche Verbesserung auf der Composite Unified Huntington's Disease Rating Scale (cUHDRS) gegenüber dem Ausgangswert um +0,64 Punkte, verglichen mit einer aufgrund der natürlichen Krankheitsentwicklung zu erwartenden
More news about: Skyhawk Therapeutics
Jan 28, 2026, 12:09 ET Skyhawk Therapeutics Umumkan Hasil Sementara Uji Klinis SKY-0515 Tahap 1 Selama Sembilan Bulan Pada Pasien Sebagai Pengobatan Penyakit Huntington
Temuan uji klinis pada bulan ke sembilan ini menunjukkan peningkatan rata-rata pada Composite Unified Huntington's Disease Rating Scale dari nilai dasar +0,64 poin, dibandingkan riwayat alamiah perkiraan penurunan cUHDRS sebesar -0,73 poin selama sembilan bulan pada pasien
More news about: Skyhawk Therapeutics
Jan 28, 2026, 03:50 ET Skyhawk Therapeutics、ハンチントン病治療薬SKY-0515の第I相臨床試験における患者の9か月中間結果を発表
傾向スコアの重み付けに基づいたハンチントン病統一評価スケール（Composite Unified Huntington's Disease Rating Scale）において、症状のある患者の9か月間の自然歴で予想される悪化点数が-0.73点であるのに対し、本試験の9か月間の所見におけるベースラインからの平均改善点は+0.64点となりました。Skyhawkはまた、SKY-0515第II相FALCON-HD試験を世界規模に拡大したことを発表しました。現在Skyhawkは、90人以上の患者に薬を投与しています。ボストン、2026年1月28日/PRNewswire/
More news about: Skyhawk Therapeutics
Jan 28, 2026, 03:11 ET Společnost Skyhawk Therapeutics oznamuje průběžné výsledky za devět měsíců u pacientů z 1. fáze klinického hodnocení přípravku SKY-0515 pro léčbu Huntingtonovy choroby
Výsledky za devět měsíců ukazují průměrné zlepšení v hodnotě Composite Unified Huntington's Disease Rating Scale oproti výchozí hodnotě +0,64 bodu na základě vážení skóre náchylnosti ve srovnání s přirozeným očekávaným zhoršením cUHDRS u symptomatických pacientů o -0,73 bodu.
More news about: Skyhawk Therapeutics
Jan 27, 2026, 22:10 ET Spoločnosť Skyhawk Therapeutics oznamuje predbežné výsledky u pacientov z fázy 1 klinického skúšania lieku SKY-0515 za deväť mesiacov liečby Huntingtonovej choroby
Deväťmesačné zistenia ukazujú priemerné zlepšenie v zjednotenej stupnici hodnotenia Huntingtonovej choroby (Composite Unified Huntington's Disease Rating Scale, cUHDRS) oproti východiskovej hodnote o +0,64 bodu, v porovnaní s prirodzeným očakávaným zhoršením cUHDRS u symptomatických
More news about: Skyhawk Therapeutics
Jan 27, 2026, 09:40 ET Skyhawk Therapeutics ogłasza dziewięciomiesięczne wyniki pośrednie badań klinicznych fazy 1 nad lekiem SKY-0515 stosowanym w leczeniu choroby Huntingtona
Wyniki z dziewięciu miesięcy pokazują średnią poprawę w Ujednoliconej Skali Oceny Choroby Huntingtona (Composite Unified Huntington's Disease Rating Scale, cUHDRS) o +0,64 punktu w stosunku do wartości wyjściowej, w porównaniu z przewidywanym pogorszeniem w naturalnym przebiegu
More news about: Skyhawk Therapeutics
Jan 27, 2026, 08:00 ET Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease
Nine-month findings show mean improvement in Composite Unified Huntington's Disease Rating Scale from baseline of +0.64 points, compared to natural history expected worsening of cUHDRS in symptomatic patients of -0.73 points over nine months, based on propensity score weighting.
More news about: Skyhawk Therapeutics
Jan 27, 2026, 08:00 ET Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease
Nine-month findings show mean improvement in Composite Unified Huntington's Disease Rating Scale from baseline of +0.64 points, compared to natural history expected worsening of cUHDRS in symptomatic patients of -0.73 points over nine months, based on propensity score weighting.
More news about: Skyhawk Therapeutics